STADA Arzneimittel

A co-development agreement has been formed by Xbrane Biopharma and STADA Arzeneimittel for the development of Xlucane — a biosimilar to Lucentis (ranibizumab), which is mainly used for the treatment of wet age-related macular degeneration (AMD). Read more


The use of image-based technology is quickly expanding in logistics. It enables processes to be configured more efficiently and products to be traced seamlessly. Pharmaceutical company STADA Arzneimittel AG, a specialist in the production of... Read more